XTX Topco Ltd Invests $3.92 Million in AbbVie Inc. $ABBV

XTX Topco Ltd purchased a new stake in AbbVie Inc. (NYSE:ABBV) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 21,132 shares of the company’s stock, valued at approximately $3,923,000.

A number of other hedge funds have also recently modified their holdings of ABBV. Aviso Financial Inc. boosted its holdings in AbbVie by 4.8% in the 2nd quarter. Aviso Financial Inc. now owns 10,764 shares of the company’s stock valued at $1,998,000 after purchasing an additional 494 shares during the last quarter. One Charles Private Wealth Services LLC lifted its stake in shares of AbbVie by 11.5% in the 2nd quarter. One Charles Private Wealth Services LLC now owns 5,341 shares of the company’s stock valued at $991,000 after purchasing an additional 550 shares during the last quarter. NDVR Inc. boosted its stake in AbbVie by 3.5% during the second quarter. NDVR Inc. now owns 2,435 shares of the company’s stock worth $452,000 after buying an additional 83 shares during the period. Steward Partners Investment Advisory LLC increased its holdings in AbbVie by 25.7% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 342,136 shares of the company’s stock valued at $63,507,000 after purchasing an additional 70,051 shares during the last quarter. Finally, Atalanta Sosnoff Capital LLC grew its stake in shares of AbbVie by 23.4% in the second quarter. Atalanta Sosnoff Capital LLC now owns 511,778 shares of the company’s stock valued at $94,996,000 after buying an additional 97,017 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

NYSE:ABBV opened at $231.83 on Wednesday. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. The company has a market capitalization of $409.74 billion, a P/E ratio of 110.40, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. The firm has a 50-day moving average price of $227.36 and a two-hundred day moving average price of $206.12. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is presently 524.24%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ABBV shares. Scotiabank began coverage on AbbVie in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective for the company. Citigroup dropped their price target on AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research note on Monday, November 3rd. Hsbc Global Res cut AbbVie from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 1st. BMO Capital Markets upped their target price on shares of AbbVie from $215.00 to $240.00 and gave the company an “outperform” rating in a report on Friday, September 12th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $241.85.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.